Table 3

Sensitivity analyses
Sensitivity analysis Colon cancer patients Controls Odds Ratio 95% confidence intervals p-value
# with at least 1 prescription # of nonusers # with at least 1 prescription # of nonusers
5-year follow-up prior to index date
main analysis: maximum numbers of participants in different years of follow-up 2588 18872 9435 69896 0.51 (0.29, 0.90) 0.021
using the same 5-year follow-up group for 3- year and 1-year analyses 2588 18872 9435 69896 0.51 (0.29, 0.90) 0.021
participants without any occurance of myocardial infarction or congestive heart failure 2048 17238 7584 64687 0.57 (0.30, 1.08) 0.085
patients without any occurance of peptic ulcer disease 1112 12374 4597 52859 0.61 (0.19, 1.97) 0.412
patients with any occurance of peptic ulcer disease 1476 6498 4838 17037 0.31 (0.08, 1.19) 0.089
patients without any occurance of colon or rectal polyps 2520 18447 9432 69895 0.55 (0.30, 1.98) 0.044
3-year follow-up prior to index date
main analysis: maximum numbers of participants in different years of follow-up 2393 25117 8293 90607 0.58 (0.39, 1.86) 0.007
using the same 5-year follow-up group for 3- year analysis 2376 19084 8489 70842 0.60 (0.40, 0.89) 0.011
participants without any occurance of myocardial infarction or congestive heart failure 1990 23458 7001 85573 0.61 (0.39, 0.94) 0.026
patients without any occurance of peptic ulcer disease 1190 17857 4737 74165 0.71 (0.37, 1.36) 0.304
patients with any occurance of peptic ulcer disease 1203 7260 3556 16442 0.49 (0.20, 1.20) 0.117
patients without any occurance of colon or rectal polyps 2316 18671 8488 70841 0.61 (0.40, 0.91) 0.016
1-year follow-up prior to index date
main analysis: maximum numbers of participants in different years of follow-up 1264 31959 4153 121708 0.60 (0.46, 0.80) <.001
using the same 5-year follow-up group for 3-year and 1-year analyses 1247 20213 4380 74951 0.61 (0.46, 0.81) 0.001
participants without any occurance of myocardial infarction or congestive heart failure 1139 33696 3807 118187 0.59 (0.43, 0.79) 0.001
patients without any occurance of peptic ulcer disease 765 28501 2951 111326 0.79 (0.54, 1.15) 0.227
patients with any occurance of peptic ulcer disease 499 3458 1202 10382 0.56 (0.17, 1.85) 0.340
patients without any occurance of colon or rectal polyps 1216 19797 4379 74951 0.61 (0.46, 0.81) 0.001
6-month follow-up prior to index date
main analysis: maximum numbers of participants in different years of follow-up 822 35401 2619 123242 0.72 (0.56, 0.93) 0.012
using the same 5-year follow-up group for 3- year and 1-year analyses 806 20654 2747 76584 0.72 (0.56, 0.93) 0.013
participants without any occurance of myocardial infarction or congestive heart failure 744 34091 2411 119583 0.70 (0.53, 0.91) 0.009
patients without any occurance of peptic ulcer disease 491 28775 1855 112422 0.95 (0.68, 1.33) 0.777
patients with any occurance of peptic ulcer disease 331 6626 764 10820 0.67 (0.24, 1.88) 0.443
patients without any occurance of colon or rectal polyps 786 20227 2747 76583 0.71 (0.55, 0.92) 0.009
3-month follow-up prior to index date
main analysis: maximum numbers of participants in different years of follow-up 533 35690 1652 124209 0.80 (0.64, 1.01) 0.056
using the same 5-year follow-up group for 3-year and 1-year analyses 521 20939 1721 77610 0.80 (0.64, 1.01) 0.057
participants without any occurance of myocardial infarction or congestive heart failure 480 34355 1502 120492 0.78 (0.61, 0.98) 0.036
patients with any occurance of peptic ulcer disease 209 6748 511 11073 0.76 (0.31, 1.85) 0.550
patients without any occurance of colon or rectal polyps 507 20506 1721 77609 0.79 (0.63, 0.99) 0.038

Yang et al.

Yang et al. BMC Cancer 2012 12:582   doi:10.1186/1471-2407-12-582

Open Data